中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
13,14-seco seco withaphysalins from Physalis minima and their inhibitory effects on NLRP3 inflammasome activation

文献类型：期刊论文

作者Hu, Bintao6,7; Peng, Xia5; Tang, Chunping6,7; Geng, Meiyu3,4,5,7; Yao, Sheng2,4,6,7; Ai, Jing3,4,7; Ye, Yang1,4,6,7
刊名BIOORGANIC CHEMISTRY
出版日期2024-10-01
卷号151页码:12
关键词Physalis minima NLRP3 Anti-inflammatory 13,14-seco withaphysalin
ISSN号0045-2068
DOI10.1016/j.bioorg.2024.107630
通讯作者Yao, Sheng(yaosheng@simm.ac.cn) ; Ai, Jing(jai@simm.ac.cn) ; Ye, Yang(yye@simm.ac.cn)
英文摘要Seven new 13,14-seco withaphysalins including two new skeletons (1 and 9) were isolated from the whole plants of Physalis minima, together with three known analogues (6-8). Among them, compound 1 was an extremely rare steroid with a 6, 8-cyclo ring. Their structures were established by extensive analysis of spectroscopic data, experimental electronic circular dichroism measurements, and single-crystal X-ray crystallographic analysis. In Raw264.7 cells, compounds 1-3, 5, 6, and 8 demonstrated potent ability to reduce the NLRP3-dependent caspase-1 activation. Among these compounds, 1 and 2 showed a superior potential, consistently concentrationdependent downregulating NLRP3-dependent proinflammatory cytokine IL-1/i production in macrophage. Mechanistically, compounds 1 and 2 reduced the cleavage of caspase-1 and GSDMD, and exhibited no obvious impact both on the NF-kappa B activation and the expression of NLRP3 and IL-1/i, suggesting that the compounds target the activation of the NLRP3 pathway mainly by inhibiting the NLRP3 inflammasome activation step rather than the priming step.
WOS关键词WITHANOLIDES ; MECHANISM
资助项目Natural Science Foundation of China for Innovation Research Group[81821005] ; National Key R & D Program of China[2017YFE0195100] ; National Key R & D Program of China[2022YFE0203600] ; National Natural Science Foundation of China[81903485] ; Science and Technology Commission of Shanghai Municipality[19431908100] ; Collaborative Innovation Cluster Project of Shanghai Municipal Commission of Health and Family Planning[2020CXJQ02] ; Key-Area Research and Development Program of Guangdong Province[2020B0303070002] ; High-level new R D institute[2019B090904008] ; High-level Innovative Research Institute from Department of Science and Technology of Guangdong Province[2021B0909050003] ; Department of Science and Technology of Guangdong Province ; Project of Shanghai Institute of Materia Medica, Chinese Academy of Sciences[SIMM0120231001]
WOS研究方向Biochemistry & Molecular Biology ; Chemistry
语种英语
WOS记录号WOS:001281418700001
出版者ACADEMIC PRESS INC ELSEVIER SCIENCE
源URL[http://119.78.100.183/handle/2S10ELR8/312583]  
专题新药研究国家重点实验室
通讯作者Yao, Sheng; Ai, Jing; Ye, Yang
作者单位1.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Zhongshan Inst Drug Discovery, Zhongshan 528400, Peoples R China
3.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Shandong, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
5.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
6.Chinese Acad Sci, Shanghai Inst Mat Med, Nat Prod Chem Dept, Shanghai 201203, Peoples R China
7.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Hu, Bintao,Peng, Xia,Tang, Chunping,et al. 13,14-seco seco withaphysalins from Physalis minima and their inhibitory effects on NLRP3 inflammasome activation[J]. BIOORGANIC CHEMISTRY,2024,151:12.
APA Hu, Bintao.,Peng, Xia.,Tang, Chunping.,Geng, Meiyu.,Yao, Sheng.,...&Ye, Yang.(2024).13,14-seco seco withaphysalins from Physalis minima and their inhibitory effects on NLRP3 inflammasome activation.BIOORGANIC CHEMISTRY,151,12.
MLA Hu, Bintao,et al."13,14-seco seco withaphysalins from Physalis minima and their inhibitory effects on NLRP3 inflammasome activation".BIOORGANIC CHEMISTRY 151(2024):12.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。